The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.
Abstract
PURPOSE: CAMPATH-1H is a human immunoglobulin G1 (IgG1) anti-CD52 monoclonal antibody (MAb) that binds to nearly all B- and T-cell lymphomas and leukemias. We report the results of a multicenter phase II trial that used CAMPATH-1H in previously chemotherapy-treated patients with chronic lymphocytic leukemia (CLL). MATERIALS AND METHODS: Twenty-nine patients who had relapsed after an initial response (n = 8) or were refractory (n = 21) to chemotherapy were treated with CAMPATH-1H administered as a 30-mg 2-hour intravenous (IV) infusion thrice weekly for a maximum period of 12 weeks. RESULTS: Eleven patients (38%) achieved a partial remission (PR) and one (4%) a complete remission (CR) (response rate, 42%; 95% confidence interval [CI], 23% to 61%). Three of eight patients (38%) with a relapse and nine of 21 refractory patients (43%) responded to CAMPATH-1H therapy. CLL cells were rapidly eliminated from blood in 28 of 29 patients (97%). CR in the bone marrow was obtained in 36% and splenomegaly resolved completely in 32%. Lymphadenopathy was normalized in only two patients (7%). The median response duration was 12 months (range, 6 to 25+). World Health Organization (WHO) grade IV neutropenia and thrombocytopenia developed in three (10%) and two patients (7%), respectively. Neutropenia and thrombocytopenia recovered in most responding patients during continued CAMPATH-1H treatment. Lymphopenia (< 0.5 x 10(9)/L) occurred in all patients. Two patients had opportunistic infections and four had bacterial septicemia. CONCLUSION: CAMPATH-1H had significant activity in patients with advanced and chemotherapy-resistant CLL. The most pronounced effects were noted in blood, bone marrow, and spleen. Preferential clearance of blood may allow harvesting of uncontaminated blood stem cells for use in high-dose chemotherapy protocols.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical staging of chronic lymphocytic leukemia
Rai, K., Sawitsky, A., Cronkite, E., Chanana, A., Levy, R., & Pasternack, B. (1975) · Blood · doi:10.1182/blood.v46.2.219.219 · Cited by 2,784
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H
Hale, G., Clark, M. R., Marcus, R., Winter, G., Dyer, M. J. S., Phillips, J. M., Riechmann, L., & Waldmann, H. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90588-0 · Cited by 688
Self-citationCheson, B. D., Bennett, J. M., Rai, K. R., Grever, M. R., Kay, N. E., Schiffer, C. A., Oken, M. M., Keating, M. J., Boldt, D. H., Kempin, S. J., et al. (1988) · American Journal of Hematology · doi:10.1002/ajh.2830290307 · Cited by 390
Humanised monoclonal antibody therapy for rheumatoid arthritis
Isaacs, J. D., Hale, G., Cobbold, S. P., Waldmann, H., Watts, R. A., Hazleman, B. L., & Keogan, M. T. (1992) · The Lancet · doi:10.1016/0140-6736(92)92294-p · Cited by 308
ÖSterborg, A., Fassas, A. S., Anagnostopoulos, A., Dyer, M. J. S., Catovsky, D., & Mellstedt, H. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.450989.x · Cited by 228
Self-citationEffect of Campath-1H antibody on human hematopoietic progenitors in vitro
Gilleece, M., & Dexter, T. (1993) · Blood · doi:10.1182/blood.v82.3.807.807 · Cited by 217
Tallman, M., & Hakimian, D. (1995) · Blood · doi:10.1182/blood.v86.7.2463.2463 · Cited by 149
Hale, G., Clark, M., & Waldmann, H. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.5.3056 · Cited by 142
Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen
Meng-Qi, X., Hale, G., & Waldmann, H. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90155-5 · Cited by 111
Maloney, D. G., Brown, S. L., Czerwinski, D. K., Liles, T. M., Hart, S. M., Miller, R., & Levy, R. (1992) · Blood · doi:10.1182/blood.v80.6.1502.1502 · Cited by 78
Dyer, M. J. S., Hale, G., Marcus, R. E., & Waldmann, H. (1990) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199009053522 · Cited by 71
Self-citationLim, S., Davey, G., & Marcus, R. E. (1993) · The Lancet · doi:10.1016/0140-6736(93)93024-u · Cited by 30
Cited by
Keating, M. J., Flinn, I., Jain, V., Binet, J.-L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3554 · Cited by 948
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
“This concept is most clearly illustrated by data for the monoclonal anti-CD52 antibody Campath- Oncogene 1H, found to be much more efficient at clearing NHL cells from blood and marrow than from lymph nodes, leading to studies of this agent in CLL (Osterborg et al., 1997).”
BackgroundWinkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Yeo, W., Chan, T. C., Leung, N. W. Y., Lam, W. Y., Mo, F. K. F., Chu, M. T., Chan, H. L. Y., Hui, E. P., Lei, K. I. K., Mok, T. S. K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0182 · Cited by 636
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda, W. G., Kipps, T. J., Mayer, J., Stilgenbauer, S., Williams, C. D., Hellmann, A., Robak, T., Furman, R. R., Hillmen, P., Trneny, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3187 · Cited by 590
Self-citation
Metadata
- Authors
- Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y., Catovsky, D., & Mellstedt, H.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-04
- Volume
- 15
- Issue
- 4
- Pages
- 1567-1574
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1833241997
- Cited by
- 512
- References
- 13
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.